Ironwood Pharmaceuticals, Inc.
Symbol: IRWD
NASDAQ
6.74
USDDzisiejsza cena rynkowa
-1.0492
Wskaźnik P/E
0.1032
Wskaźnik PEG
1.07B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Ironwood Pharmaceuticals, Inc. (IRWD) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 92.2 | 656.2 | 620.1 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 129.1 | 115.5 | 114 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 1.3 | 1.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 12 | 7.7 | 9.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 233.3 | 780.6 | 745.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 18.2 | 20.3 | 22.9 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 3.7 | 0 | 0 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3.7 | -15.1 | -24.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 212.3 | 283.7 | 333.3 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 3.6 | 15.9 | 25.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 237.8 | 319.9 | 381.7 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 7.8 | 0.5 | 0.9 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 202.7 | 3.1 | 120 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 1.2 | 0.7 | 0.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 498.3 | 412.9 | 355.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 64.3 | 22 | 1.3 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 541.3 | 422.6 | 359.3 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14.5 | 19.7 | 21.6 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 817.4 | 448.1 | 521 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -1698.6 | -696.4 | -937.6 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -3 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1355.2 | 1348.6 | 1543.4 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 715.5 | 415.9 | 475.8 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 623.4 | -240.3 | -144.3 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1002.2 | 175.1 | 528.4 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 72.6 | 65.7 | -333.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 32 | 27 | 22.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 11.3 | 2.8 | 17.7 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.9 | 8 | 7.7 | |||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 12.4 | -8.1 | -2.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -2 | 2.9 | 12.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 1068.2 | 1.7 | 25.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1026 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1026.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -300 | -120.7 | 0 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 6.4 | 9.5 | 19.6 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -126.4 | -24.1 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -111.2 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 570.8 | 111.2 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 277.2 | -237.6 | -4.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -565.3 | 36.1 | 257.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 92.2 | 657.9 | 621.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 657.5 | 621.9 | 364.8 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 183.4 | 273.8 | 261.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 183.2 | 273.6 | 261.6 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 442.7 | 410.6 | 413.8 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 441.2 | 409.2 | 412.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 232.1 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 233.7 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 19 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1.6 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 209 | 250.3 | 232.3 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -948.1 | 252.4 | 200.7 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 83.5 | 77.4 | -327.8 | |||||||||||||||||
income-statement-row.row.net-income | 0 | -1002.2 | 175.1 | 528.4 |
Często zadawane pytania
Ile wynosi Ironwood Pharmaceuticals, Inc. (IRWD) aktywów ogółem?
Ironwood Pharmaceuticals, Inc. (IRWD) całkowite aktywa to 471073000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to N/A.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.996.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 1.174.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -2.264.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -2.120.
Co to jest Ironwood Pharmaceuticals, Inc. (IRWD) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -1002239000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 715538000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 232124000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 0.000.